Study of CHS-114 and toripalimab for advanced solid tumors
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a new drug combo (CHS-114 + toripalimab) for people with advanced solid tumors like stomach, esophageal, or colorectal cancer that have already been treated. It aims to see if adding these drugs can help control the cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of cancer that is advanced (has spread) or cannot be removed by surgery, specifically stomach, gastro-esophageal junction, esophageal adenocarcinoma, esophageal squamous cell carcinoma, or colorectal cancer.
- Your cancer must have continued to grow after at least one prior treatment, unless you are in the first-line esophageal squamous cell group.
- You must have at least one tumor that can be seen on a scan (like a CT scan).
- You must be willing to provide a tumor tissue sample (from a biopsy or previous surgery) before starting the study.
- You cannot have untreated or symptomatic brain metastases, certain other active cancers, or a history of severe allergic reactions to antibody treatments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination (RC118 plus toripalimab/RC148) for people with advanced stomach or gastroesophageal junction cancer. It’s for those whose cancer has not responded to standard treatment and whose tumors have a specific protein called Claudin 18.2.
This trial tests a new combination of two drugs (LTC004 and toripalimab) for people with advanced solid tumors that have stopped responding to standard immunotherapy. It aims to see if this combination can help when immunotherapy alone no longer works.
This trial tests a new combination of two medications (IPG7236 and Toripalimab) for people with advanced solid tumors that have not responded to standard therapies. The goal is to see if the combination is safe and effective.
This study tests a new combination drug called HS-20093 for people with advanced solid tumors. It aims to see if it is safe and works against cancer that hasn't responded to other treatments.
This study tests a combination of two drugs (LM-108 and toripalimab) for people with advanced solid tumors that have a specific marker called MSI-H or dMMR. It is for those whose cancer has grown after previous immunotherapy treatment.
This trial tests a new drug that may help people with advanced solid tumors, including liver, stomach, and brain cancers. It is for patients whose cancer has not responded to standard treatments or who cannot have them. The study aims to find the right dose and check safety and effectiveness.
Hear when a new Metastatic Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.